Biblio Discovery — Demo Discovery Service

4 results for "Yu-Cheng Chang"

Showing 1–4 · 0.56 seconds · RSS

  1. Journal Article Full text

    The Therapeutic Potential and Mechanisms of Action of Quercetin in Relation to Lipopolysaccharide-Induced Sepsis In Vitro and In Vivo

    Yu-Cheng Chang; Ming-Han Tsai; Wayne Huey-Herng Sheu et al.

    PLoS ONE, Vol. 8 No. 11 · 2013 · English · PLOS Scopus

    Sepsis caused by Gram-negative bacterial infection is characterized by extensive inflammatory cytokine production, which leads to multiple organ failure and a high lethality rate. Therefore, compounds that are able to alleviate profound inflammatory responses may have therapeutic potential in…

  2. Journal Article Full text

    The Population Effective Dose of Medical Computed Tomography Examinations in Taiwan for 2013

    Da-Ming Yeh; Hui-Yu Tsai; Yen-Sheng Tyan et al.

    PLOS ONE, Vol. 11 No. 10 · 2016 · English · PLOS Scopus

    Purpose: To evaluate the annual effective dose per capita attributed to computed tomography (CT) examinations in 2013 and to predict the population effective dose from 2000 to 2013 in Taiwan. Methods: A CT examination database collected from 30 hospitals was divided into 22 procedures and…

  3. Journal Article Full text

    YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells

    Chun-Chia Cheng; Jungshan Chang; Stanley Ching-Cheng Huang et al.

    PLOS ONE, Vol. 12 No. 8 · 2017 · English · PLOS Scopus

    Cancer stem cell survival is the leading factor for tumor recurrence after tumor-suppressive treatments. Therefore, specific and efficient inhibitors of cancer stemness must be discovered for reducing tumor recurrence. YM155 has been indicated to significantly reduce stemness-derived tumorsphere…

  4. Journal Article Full text

    Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-T SCM cells using a Quantum pBac -based CAR-T engineering system

    Peter S. Chang; Yi-Chun Chen; Wei-Kai Hua et al.

    PLOS ONE, Vol. 19 No. 8 · 2024 · English · PLOS Scopus

    CD19-targeted chimeric antigen receptor (CAR) T cell therapies have driven a paradigm shift in the treatment of relapsed/refractory B-cell malignancies. However, >50% of CD19-CAR-T-treated patients experience progressive disease mainly due to antigen escape and low persistence. Clinical prognosis…